ACADSB and nonpapillary renal cell carcinoma: The results showed that the high expression of ACADSB promoted the drug resistance of ccRCC cell lines to FTY 720 and ARRY-520 but enhanced the drug sensitivity of ccRCC cell lines to cisplatin, vorinostat, SN-38, and other drugs (Figure 11(a)).